Smart Inhalers Market Report 2026

The smart inhalers market size has grown strongly in recent years. It will grow from $1.8 billion in 2025 to $1.98 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rise in asthma prevalence, poor medication adherence rates, growth of respiratory diseases, inhaler technology improvements, digital health awareness.

The smart inhalers market size is expected to see strong growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to remote patient monitoring growth, expansion of value-based care, smartphone health app usage, regulatory approvals, pediatric asthma management focus. Major trends in the forecast period include integration of usage tracking sensors, growth of app-connected inhalers, expansion of asthma management platforms, adoption of real-time adherence alerts, increased payer support.

The rising prevalence of chronic respiratory diseases (CRDs) is expected to drive the growth of the smart inhaler market in the coming years. CRDs include a variety of long-term conditions that affect the airways and other parts of the lungs. Smart inhalers help manage diseases such as asthma and COPD by tracking usage and providing reminders for missed doses, ensuring consistent medication adherence to control symptoms and prevent exacerbations. For example, in December 2023, the National Center for Biotechnology Information, a US-based government agency, reported that the number of COPD cases is projected to increase by 112 million, reaching 592 million by 2050, representing 9.5% of the eligible population. Consequently, the rising prevalence of chronic respiratory diseases is fueling the smart inhaler market.

Key companies in the smart inhaler market are focusing on technological innovations, such as universal dose counters and connected inhaler systems, to improve medication adherence, usability, and patient monitoring. Universal dose counters attach to various inhaler types to accurately track doses taken, enhancing adherence and enabling remote monitoring. For instance, in June 2024, Aseptika, a UK-based digital health company, launched the PUFFClicker3 universal inhaler dose counter. The device fits a wide range of inhalers, providing precise dose tracking, improving adherence, and allowing healthcare providers to monitor inhaler use remotely for patients with asthma and COPD. By integrating clear counters and digital tracking, PUFFClicker3 aims to improve patient outcomes and support effective management of chronic respiratory diseases.

In December 2024, Adherium Ltd., an Australia-based digital health company, partnered with Tenovi to advance remote patient monitoring solutions for respiratory conditions. The collaboration focuses on increasing patient engagement, improving medication adherence, and providing real-time health insights, supporting better disease management and driving innovation in digital respiratory care. Tenovi is a US-based technology company specializing in remote monitoring platforms for chronic health conditions.

Major companies operating in the smart inhalers market are Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Lupin Limited, Aptar Group Inc., Nemera France SAS, Vectura Group Limited, Propeller Health, Findair Sp.z o.o., Biocorp Production, Cohero Health Inc., Pneuma Respiratory Inc., Amiko Digital Health Limited, AireHealth Inc., Adherium Ltd., Zeolr Technologies Pvt Ltd., H&T Presspart Manufacturing Ltd., Cognita Labs LLC, Teva Respiratory LLC, AstraZeneca Respiratory Devices.

North America was the largest region in the smart inhalers market in 2025. The regions covered in the smart inhalers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart inhalers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised prices in the smart inhalers market by increasing the cost of imported sensors, connectivity modules, plastic components, and pharmaceutical-grade inhaler parts. Hospital pharmacies and retail pharmacies in Asia-Pacific and Europe are most affected due to reliance on global device manufacturers. These higher costs can slow adoption of connected DPIs and MDIs for asthma and COPD management. However, tariffs are encouraging domestic production and device assembly, improving long-term affordability in the smart inhalers market.

The smart inhalers market research report is one of a series of new reports that provides smart inhalers market statistics, including smart inhalers industry global market size, regional shares, competitors with a smart inhalers market share, detailed smart inhalers market segments, market trends and opportunities, and any further data you may need to thrive in the smart inhalers industry. This smart inhalers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Smart inhalers are medical devices that combine connectivity with a mobile app, often via Bluetooth. They are used to enhance the user experience and support more personalized treatment decisions for individuals with chronic lung conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The main types of smart inhalers include dry powdered inhalers (DPIs) and metered dose inhalers (MDIs). Dry powdered inhalers (DPIs) deliver medications, such as inhaled corticosteroids, directly into the lungs. They are used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, homecare settings, and other healthcare facilities.

The smart inhalers market consists of sales of pressurized MDIs (metered-dose inhalers), breath-actuated MDIs (metered-dose inhalers), and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.